Table 3.
Univariate and multivariate Cox proportional hazard analysis of APLN expression and OS for patients with cervical cancer in the TCGA cohort.
| Characteristics | Total (N) | HR (95% CI) univariate analysis | p Value univariate analysis | HR (95% CI) multivariate analysis | p Value multivariate analysis |
|---|---|---|---|---|---|
| N stage (N1 vs N0) | 193 | 2.695 (1.358–5.349) | 0.005 a | 2.887 (1.206–6.912) | 0.017 a |
| Clinical stage (stage II and stage III and stage IV vs stage I) | 297 | 1.429 (0.896–2.280) | 0.134 | ||
| Radiation therapy (yes vs no) | 304 | 1.153 (0.681–1.951) | 0.596 | ||
| Histological type (squamous vs adenosquamous cell carcinoma) | 304 | 1.010 (0.530–1.926) | 0.976 | ||
| Menopause status (post vs pre and peri) | 231 | 1.275 (0.744–2.185) | 0.376 | ||
| Histologic grade (G3 and G4 vs G1 and G2) | 272 | 0.889 (0.527–1.502) | 0.661 | ||
| Age (>50 vs ≤50) | 304 | 1.317 (0.825–2.101) | 0.248 | ||
| PIK3CA status (Mut vs WT) | 286 | 1.011 (0.599–1.707) | 0.967 | ||
| Primary therapy outcome (PD, SD, and PR vs CR) | 217 | 13.514 (7.250–25.189) | <0.001 a | 7.877 (2.792–22.222) | <0.001 a |
| Race (Asian and Black or African American vs White) | 259 | 0.841 (0.427–1.658) | 0.618 | ||
| APLN (high vs low) | 304 | 1.942 (1.192–3.164) | 0.008 a | 3.428 (1.390–8.456) | 0.007 a |
CI: confidence interval; CR: complete response; HR: hazard ratio; PD: progressive disease; PR: partial response; SD: stable disease.
a
Statistically significant.